{"filings":[{"id":98390,"accession_number":"0001096906-26-000685","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders re-elect Hoyer & Beeson, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ernst G. Hoyer re-elected with 1,330,333 for; 1,070,640 withheld; 372,329 broker non-votes.","James H. Beeson re-elected with 1,708,941 for; 692,032 withheld; same broker non-votes.","Ratification of Haynie & Co. as auditor approved: 2,753,278 for, 16,273 against, 3,751 abstentions.","Say-on-pay proposal approved: 2,354,919 for, 38,451 against, 7,603 abstentions; company to continue annual advisory votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98389,"accession_number":"0001096906-26-000602","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products announces Q1 2026 financial results; figures not available in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release attached as Exhibit 99.1 includes Q1 2026 financial information and forward-looking statements.","Exact figures (revenue, EPS, etc.) are not available in the provided filing text excerpt.","Refer to the full exhibit for detailed performance data and guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":8722000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113817,"accession_number":"0001096906-26-000161","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products releases FY2025 earnings; no specifics in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Utah Medical Products reported Q4 and FY2025 results via press release dated January 29, 2026.","Filing references financial data and forward-looking statements in Exhibit 99.1.","Specific financial figures (revenue, EPS, guidance) were not included in the provided excerpt.","Confidence is low due to incomplete exhibit text; full details may be in attached press release."],"consensus_eps_estimate":null,"consensus_eps_actual":3.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":38520000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130226,"accession_number":"0001096906-25-001733","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["5.02","8.01","9.01","99.1"],"status":"ready","headline":"Utah Medical Products appoints director, increases quarterly dividend to $0.31/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Kevin Timken to board, increasing size to 6; he joins Audit and Compensation committees.","Timken received 10,000 stock options at $58.10, vesting over 4 years; quarterly fee $7,650 pro-rated.","Quarterly cash dividend raised to $0.31 per share, payable Jan 5, 2026 to holders of record Dec 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130225,"accession_number":"0001096906-25-001708","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products Q3 2025 earnings released; financial data not available in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Q3 and nine-month period ended September 30, 2025 results reported via press release.","Specific revenue, EPS, and segment figures are not present in the provided text.","Forward-looking statements for 2025 and beyond accompany the release."],"consensus_eps_estimate":null,"consensus_eps_actual":2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":29475000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146789,"accession_number":"0001096906-25-001180","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products files 8-K with Q2 2025 results; specifics not extractable from filed text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated July 24, 2025 covers three and six months ended June 30, 2025.","No financial figures (revenue, EPS, net income) were included in the provided filing excerpt.","The filing is furnished under Item 2.02 and includes forward-looking statements.","Investors should consult the full Exhibit 99.1 press release for actual results."],"consensus_eps_estimate":null,"consensus_eps_actual":1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":19663000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165219,"accession_number":"0001096906-25-000679","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"UTMD annual meeting: director Carrie Leigh re-elected despite majority withheld votes; board rejects resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Carrie Leigh received 665,574 for, 1,762,500 withheld; board did not accept her tendered resignation.","Ratification of Haynie & Co. as independent auditor passed with 3,148,121 for, 10,548 against, 1,973 abstain.","Advisory vote on executive compensation approved with 2,383,762 for, 39,327 against, 4,985 abstain, and 732,568 broker non-votes.","Company will continue annual advisory votes on executive compensation until next required frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165218,"accession_number":"0001096906-25-000625","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products Q1 2025 results released; no specific figures in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Q1 2025 financial results released on April 29, 2025 for Utah Medical Products.","Revenue, net income, EPS, and segment details are not available in the filing excerpt provided.","Forward-looking statements for 2025 and beyond are referenced but not quoted.","Investors should consult the complete press release for full financial data."],"consensus_eps_estimate":null,"consensus_eps_actual":0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":9710000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182895,"accession_number":"0001096906-25-000095","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD reports Q4/FY2024 results; specific figures not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated Jan 28, 2025 contains financial data for three and twelve months ended Dec 31, 2024.","Specific revenue, EPS, and other metrics not provided in the filing text or exhibit excerpt.","Forward-looking statements for 2024 and beyond are included in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":3.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":40903000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199484,"accession_number":"0001096906-24-002072","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","8.01","9.01","99.1"],"status":"ready","headline":"Utah Medical Products appoints director Carrie Leigh, raises dividend 1.7% to $0.305","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increased to 6 members; appointed Carrie Leigh, daughter of CEO Kevin Cornwell, effective Nov 1, 2024.","Ms. Leigh worked at UTMD from 2004-2016, last as Global Direct End User Sales manager; now a consultant.","She received 10,000 options at $64.09/share vesting over 4 years and quarterly board fee of $7,350.","Quarterly cash dividend raised 1.7% to $0.305 per share, payable Jan 3, 2025 to holders of record Dec 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199483,"accession_number":"0001096906-24-002035","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products Q3 2024 results referenced but data missing in filing extract","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["8-K filed Oct 29, 2024 furnishes press release for three and nine months ended Sep 30, 2024.","Full financial figures and forward-looking statements are not included in the provided text.","Company ticker: UTMD."],"consensus_eps_estimate":null,"consensus_eps_actual":3.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":31745000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215513,"accession_number":"0001096906-24-001590","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products files Q2 2024 earnings release; detailed results not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company furnished financial information for three and six months ended June 30, 2024 via press release dated July 25, 2024.","Exhibit 99.1 referenced but actual financial data is missing from the provided filing text.","Forward-looking statements for 2024 and beyond are also included per the exhibit description."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":21740000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234853,"accession_number":"0001096906-24-001026","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"UTMD annual meeting: Director Richins re-elected despite majority withheld votes; board rejects resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paul Richins re-elected with 907,483 for vs 1,833,586 withheld; board declined his conditioned resignation.","Kevin Cornwell re-elected with 1,436,389 for and 1,304,680 withheld.","Ratification of auditor Haynie & Co. passed with 3,012,801 for (98.4% of votes cast).","Advisory Say-on-Pay approved with 2,662,106 for (97.3% of votes cast, excluding broker non-votes).","Broker non-votes of 324,644 present on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234852,"accession_number":"0001096906-24-000934","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products Q1 2024 earnings released; key figures not provided in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated April 25, 2024 announces Q1 2024 financial results for Utah Medical Products.","Exhibit 99.1 with detailed financial data and forward-looking statements is referenced but not fully provided.","Specific revenue, EPS, and segment results are unavailable from the excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":11340000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252705,"accession_number":"0001096906-24-000127","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD FY2023 EPS up 1% on interest income; revenue down 4%, litigation costs rise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year revenue $50.2M (-4% YoY); EPS $4.574 (+1.2%) as lower operating income offset by higher interest income.","Q4 revenue $12.3M (-9%); net income $4.3M (-6%); gross margin fell to 57.6% from 61.3%.","Operating income down 15% due to $2.9M biopharma OEM decline and $1.66M litigation costs vs $0.67M in 2022.","Cash & investments rose to $92.9M; quarterly dividend increased to $0.30/share starting Jan 2024.","Management expects further GP margin dilution in 2024 as biopharma sales projected to decline significantly."],"consensus_eps_estimate":null,"consensus_eps_actual":4.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":50224000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270186,"accession_number":"0001096906-23-002066","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01","9.01","99.1"],"status":"ready","headline":"Utah Medical Products raises quarterly dividend to $0.30, up 1.7%","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend increased to $0.30 per share, a 1.7% rise from prior rate.","Payable on January 3, 2024, to shareholders of record December 15, 2023.","Company trades on Nasdaq under ticker UTMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270185,"accession_number":"0001096906-23-002058","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products reports Q3 2023 results; financial data not provided in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated October 26, 2023 covers three and nine months ended September 30, 2023.","Exhibit 99.1 with specific financial figures was not included in the user query.","No revenue, EPS, or segment details available for summary."],"consensus_eps_estimate":null,"consensus_eps_actual":3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":37891000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287157,"accession_number":"0001096906-23-001449","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products reports Q2/H1 2023 results; details not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing references a press release with financial results for three and six months ended June 30, 2023.","Specific revenue, EPS, or segment figures are not included in the provided text.","Forward-looking statements for 2023 and beyond are mentioned but content is unavailable."],"consensus_eps_estimate":null,"consensus_eps_actual":2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":25386000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307263,"accession_number":"0001096906-23-000990","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"UTMD shareholders reject 2023 incentive plan; directors with low support remain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 Employees’ and Directors’ Incentive Plan voted down: 1,168,480 for vs 1,590,668 against.","Directors Hoyer (871,160 for, 1,926,073 withheld) and Beeson (1,277,218 for, 1,520,015 withheld) re-elected but board declined their resignations.","Advisory say-on-pay passed with 2,719,953 for vs 72,499 against; shareholders prefer annual votes.","Ratification of Haynie & Co. as auditor passed with 3,138,164 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307262,"accession_number":"0001096906-23-000901","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q1 2023: NI +19.2% to $4.2M, EPS $1.16; OUS sales +23%; cash $80.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated sales $12.5M, up 1.6% YoY; OUS sales up 23% (28% constant currency), domestic down 10%.","Operating income margin 35.5% (down from 36.7%) due to $348K higher litigation expenses.","Net income $4.2M, EPS $1.16 vs $0.96; NI margin 33.7% vs 28.7%.","Cash and investments $80.9M, up $5.9M from Dec 31, 2022; no debt.","Management reaffirms FY2023 objectives; regular quarterly dividend $0.295/share paid in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":12520000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326297,"accession_number":"0001096906-23-000240","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.","Gross margin declined to 61.3% (Q4) and 61.6% (FY22) from 62.8%/63.0% on higher manufacturing costs and raw materials.","FY22 operating income $19.8M (+4.8%) despite $670K in litigation expenses vs $22K in 2021; cash & investments rose to $75.1M.","Repurchased 30,105 shares at $82.88 in Q2 2022; quarterly dividend increased to $0.295/share effective Jan 2023 payment.","Outstanding shares 3.63M at year-end; diluted shares 3.64M; no debt on balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":4.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":52281000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344014,"accession_number":"0001096906-22-002609","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","9.01","99.1"],"status":"ready","headline":"Utah Medical Products increases quarterly dividend to $0.295 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Regular quarterly cash dividend increased to $0.295 per share.","Dividend payable on January 4, 2023.","Record date: close of business December 16, 2022.","Announced November 1, 2022 via press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344013,"accession_number":"0001096906-22-002547","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products reports Q3 2022 earnings; no specific figures available in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Financial information for three and nine months ended September 30, 2022 is included.","Forward-looking statements relating to 2022 and beyond are provided.","No specific revenue or EPS figures are available in this summary due to missing exhibit data."],"consensus_eps_estimate":null,"consensus_eps_actual":3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":38707000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360509,"accession_number":"0001096906-22-001712","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"Utah Medical Products reports Q2 2022 results; exhibit text incomplete in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated July 26, 2022 attached as Exhibit 99.1.","Exhibit 99.1 includes financial data for Q2 and H1 2022 and forward guidance.","Specific financial figures (revenue, EPS, etc.) not available in provided filing text.","No other material events disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":25752000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379577,"accession_number":"0001096906-22-001059","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Utah Medical Products annual meeting votes: director elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Barbara A. Payne elected as director: 1,765,558 for, 1,003,678 withheld, 418,237 broker non-votes.","Haynie & Co. ratified as independent auditor for FY 2022: 3,184,748 for, 848 against, 1,877 abstentions.","Advisory vote on executive compensation approved: 2,745,809 for, 19,901 against, 3,526 abstentions, 418,237 broker non-votes.","Company will continue annual advisory say-on-pay votes until next required frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379576,"accession_number":"0001096906-22-000948","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q1 2022 revenue +12.4%, EPS +16.6%; operating margin expands to 36.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3M, up 12.4% YoY; domestic sales +18%, OUS +4% (constant currency +7%).","Net income $3.53M (+16.9%); diluted EPS $0.96 vs $0.82 in Q1 2021.","Gross margin contracted to 61.1% from 63.4% on higher raw material and freight costs.","Cash and investments $65.9M at Mar 31, 2022, up from $61.0M at Dec 31, 2021.","No regular dividend paid in Q1 2022; special $2.00/share dividend was paid in Dec 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":12323000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397771,"accession_number":"0001096906-22-000265","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["8.01","9.01","99.1"],"status":"ready","headline":"UTMD increases quarterly dividend 1.8% to $0.29/share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend increased to $0.29/share, up 1.8% YoY.","Payable April 5, 2022; record date March 18, 2022.","Prior year same quarter dividend implied at $0.285/share (1.8% lower)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397770,"accession_number":"0001096906-22-000245","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.","Full year revenue $49.1M (+16%); gross margin expanded to 63.0% from 60.6%.","Operating income margin 38.5% vs 32.5%; adjusted EBITDA $26.5M (54.1% of sales).","Paid $2.00/share special dividend in Dec 2021 ($7.3M) plus regular $0.285; cash $60.9M.","Management projects 2022 adjusted EBITDA ~$30M, up from prior estimate of $28M."],"consensus_eps_estimate":null,"consensus_eps_actual":4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":49054000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416758,"accession_number":"0001096906-21-002618","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["8.01","9.01","99.1"],"status":"ready","headline":"Utah Medical Products declares $2.00 special dividend, replacing Q4 quarterly","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $2.00/share, total ~$7.3M, payable Dec 29, 2021 to holders of record Dec 15.","Dividend replaces normal quarterly dividend; annual dividend historically ~$4M/year.","Cash & investments at Sept 30, 2021: $64.3M, up $12.7M from Dec 31, 2020.","Rationale: unable to repurchase shares in 2021; special dividend returns cash, citing anticipated 2022 tax changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416757,"accession_number":"0001096906-21-002587","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2021-10-26T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q3 2021 EPS $1.150, revenue up 20%; 9M non-GAAP EPS $3.021, up 46%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2021 net income $4.2M (33.5% of sales), up 43.4% YoY; diluted EPS $1.150.","9M 2021 US GAAP net income $10.7M, up 44.3%; non-GAAP net income $11.0M, up 45.1%.","Cash and investments at Sep 30, 2021: $64.3M, up from $51.6M at Dec 31, 2020.","Management expects FY2021 adjusted EBITDA >$26M ($28M for 2022).","Dividend increased to $0.285/share; total 9M dividends $3.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":36140000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434323,"accession_number":"0001096906-21-001665","cik":706698,"company_name":"UTAH MEDICAL PRODUCTS INC","ticker":"UTMD","form_type":"8-K","filed_at":"2021-07-22T23:59:59+00:00","items":["2.02","9.01","99.1"],"status":"ready","headline":"UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.","GAAP EPS $0.937 (up 161%); non-GAAP (ex-UK DTL) EPS $1.044 (up 148%).","Operating income $4.765M (+141%); gross margin 61.8% vs 56.3% a year ago.","Management likely expects FY2021 adjusted EBITDA of ~$25M; TTM EBITDA $24.0M.","Cash $59.5M, no debt; quarterly dividend $0.285/share (up from $0.280)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":23568000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":203780000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}